Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the ADSs on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the ADSs from Nasdaq.
Appears in 4 contracts
Samples: Securities Purchase Agreement (Bionomics Limited/Fi), Securities Purchase Agreement (General Atlantic, L.P.), Securities Purchase Agreement (Immunocore Holdings PLC)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq the continued listing requirementsrequirements of the Nasdaq Global Select Market. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the ADSs on the Nasdaq Global Select Market and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the ADSs from Nasdaqthe Nasdaq Global Select Market.
Appears in 1 contract
Samples: Securities Purchase Agreement (BICYCLE THERAPEUTICS PLC)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq Small-Cap Market continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the ADSs Company's ADRs representing the Common Stock on the Nasdaq Small-Cap Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of such ADRs from the ADSs from NasdaqNasdaq Small-Cap Market.
Appears in 1 contract
